Published in final edited form as:

Org Lett. 2010 July 2; 12(13): 2944–2947. doi:10.1021/ol1009398.

Light-Induced Isomerization of Apoptolidin A leads to Inversion of C2-C3 Double Bond Geometry

Brian O. Bachmann*, Ruth McNees, Bruce J. Melancon, Victor P. Ghidu, Rachel Clark, Brenda C. Crews, Sean M. DeGuire, Lawrence J. Marnett, and Gary A. Sulikowski*
Departments of Chemistry and Biochemistry, Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 77842–3012

Abstract

The isolation, characterization and cytotoxicity against H292 cells of apoptolidin G are reported. Apoptolidin G is shown to be derived by a light-induced isomerization of the C2-C3 carbon-carbon double bond of apoptolidin A.

The apoptolidins are a group of macrolides produced by an actinomycete of the genus *Nocardiopsis* (FERM BP-5871).¹ Apoptolidin A (**1**), the first of the class to be identified, was described by Seto and co-workers in 1997 and determined to selectively induce apoptosis in rat glia cells expressing the E1A oncogene.^{1a,2} Various shunt metabolites have subsequently been identified from the same actinomycete by the Wender group and assigned the names and structures of apoptolidins B-F (**2–6**).³ Interest in the isolation, synthesis and study of apoptolidin macrolides is associated with their observed selective cytotoxicity against various cancer cell lines providing an opportunity for the development of a unique class of anticancer therapeutics. Based on a pharmacological analysis, apoptolidin A was demonstrated to be selectively cytotoxic to metabolically active cancer cells that do not exhibit the Warburg effect.^{4,5} It was further demonstrated that apoptolidin A inhibits F₀F₁-ATPase, however subsequent examination of apoptolidin analogs and derivatives suggests the observed in vitro cell cytotoxicity may not be solely associated with this enzymatic inhibition.⁶

The identification and biological evaluation of new apoptolidin congeners provide an opportunity to develop a structure-activity relationship among this class of natural products. Several structural modifications have been introduced to the apoptolidin A skeleton by degradation, semisynthesis and total synthesis.^{7,8} Another source of new structural types, as mentioned above, has been fermentation that to date has yielded five new metabolites (apoptolidins B-F).³ Finally, as is frequently the case in natural product isolation, unique apoptolidins have been inadvertently produced during the isolation and purification process.

gary.a.sulikowski@vanderbilt.edu, brian.bachmann@vanderbilt.edu.

Supporting Information Available Procedure for the photoisomerization of apoptolidin A to **10**. ¹H and ¹³C and COSY, TOCSY, ROESY, HSQC, HMBC spectra and HRMS for apoptolidin G (**10**).

This appears to be the case among the isoapoptolidins (7–9) that result from an acyl migration from the C19 to C20 hydroxyl group resulting in a one-atom ring expansion of the macrolactone.⁹ During the course of producing apoptolidin by fermentation we recently identified a new apoptolidin A isomerization. Herein we describe the isolation, structure elucidation and biological evaluation of this new congener (apoptolidin G).

Following apoptolidin production by *Nocardiopsis* (FERM BP-5871) we isolated a minor (less than 5 mg per liter) apoptolidin from an aged crude extract. Isolation was achieved by normal phase HPLC (10% methanol in dichloromethane) following purification by flash chromatography (silica gel, 5% methanol in dichloromethane then 15% methanol in dichloromethane). The new apoptolidin had a slightly shorter retention time than apoptolidin A (normal phase, 10% methanol/dichloromethane).

The newly identified apoptolidin closely resembled apoptolidin A by NMR analysis and displayed a blue shifted UV absorption maximum (320 to 278 nm) relative to apoptolidin A. Inspection of the ¹H NMR suggested the core of the new isolate was a 20-membered macrolactone and not the corresponding ring expanded isomer (isoapoptolidin).^{7e,9} Preliminary assignments for the new congener were based on comparison to the extant chemical shifts for apoptolidin A, which revealed that primary structural differences were apparently localized in the trienoate region from C-1 to C-8 (Tables 1 and 2).

Taken together these data implied that the new congener was likely a geometrical isomer located within the trienoate chromophore.

The remaining structural features were established by a series of two-dimensional NMR experiments. HSQC experiments were used to assign all direct ¹H-¹³C connectivities. COSY and HMBC experiments confirmed the presence of the apoptolidin A polyketide chain and all functional groups were preserved in the new congener. Long-range correlations from H19 to C1 and throughout the hemiketal region confirmed the 20-membered macrolactone linkage (Figure 3). Similarly, the positions of pendant *O*-methyl groups and sugars were verified by long-range correlations.

The geometric configurations of the trienoate double bonds were determined by analysis of a ROESY experiment as shown in Figure 3, which demonstrated that the configuration of the C2-C3 olefinic bond had inverted to the *Z* configuration and that the remaining four olefins retained the *E* configuration. This structural change resulted in conformational change of the macrolide relative to apoptolidin A resulting in rotation about bonds C3-C4 and C5-C6 as indicated by diagnostic ROESY cross peaks, including from H7 to 4-Me with concurrent anisotropic shielding of trienoate olefinic protons (H3, H5 and H7, Table 1) and shielding of corresponding vinyl methyls (2-Me, 4-Me and 6-Me, Table 1) relative to the corresponding chemical shifts observed in apoptolidin A.

The isolation of a small amount of a presumed light-induced isomer of apoptolidin A prompted us to procure more of this material for further studies. Accordingly, a sample of apoptolidin A was dissolved in acetone-*d*₆ in a borosilicate glass NMR tube. The sample was irradiated using a 275 watt sunlamp for 16 h. A similar experiment was performed using methanol-*d*₄ solution of apoptolidin A. The samples were removed from irradiation and analyzed by ¹H NMR for the appearance of a new isomer. In the acetone sample, the isomerization was clean but not complete, resulting in ~5:1 mixture of an isomerized product and apoptolidin A. In the methanol sample, isomerization was observed resulting in a similar ratio of products; however, the NMR showed other minor degradation products appeared. The sample in acetone was concentrated and the resulting photoisomerized product was purified from the mixture using flash chromatography (silica gel, 2.5% methanol in dichloromethane then 10–15% methanol in dichloromethane). The material

isolated from the direct photolysis of apoptolidin A was identical to the minor metabolite we isolated from the fermentation extract. We now suggest this macrolide be named apoptolidin G, in accord with earlier minor metabolites isolated from the apoptolidin producer FERM BP-5871.

Over twenty-five apoptolidins, derived by semisynthesis, total synthesis and isolation, have been evaluated for cytotoxicity against apoptolidin sensitive cancer cell lines. The H292 human lung cancer cell shows good sensitivity to apoptolidins and various congeners. We compared the cytotoxic effect of apoptolidin A to apoptolidin G against H292 cells. As observed earlier, apoptolidin A displayed an EC₅₀ below 50 nM when exposed to H292 cells for 4 days. In the same cell viability assay apoptolidin G showed a modest decrease in cytotoxicity (EC₅₀ 150 nM) relative to apoptolidin A. This observation is in accord with earlier SAR studies which show that considerable structural modification is tolerated within the aglycone of the apoptolidins. Notably, the observed minimal loss of cell cytotoxicity by extended irradiation of apoptolidin A with UV light has implications for future photaffinity experiments using apoptolidin A derived chemical probes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health (CA 059515). R. C. acknowledges the support of the Vanderbilt NSF-REU program (CHE 0850976). S. M. D. acknowledges the support of the Vanderbilt Chemical Biology Interface (CBI) training program (T32 GM065086).

References

1. (a) Kim JW, Adachi H, ShinYa K, Hayakawa Y, Seto H. *J Antibiot.* 1997; 50:628–630. [PubMed: 9711255] Review: (b) Daniel PT, Koert U, Schuppan J. *Angew Chem Int Ed.* 2006; 45:872–893.
2. Hayakawa Y, Kim JW, Adachi H, Shin-ya K, Fujita K, Seto H. *J Am Chem Soc.* 1998; 120:3524–3525.
3. (a) Wender PA, Sukopp M, Longcore K. *Org Lett.* 2005; 7:3025–3028. [PubMed: 15987196] (b) Wender PA, Longcore KE. *Org Lett.* 2007; 9:691–694. [PubMed: 17286376] (c) Wender PA, Longcore KE. *Org Lett.* 2009; 11:5474–5477. [PubMed: 19943700]
4. (a) Salomon AR, Voehringer DW, Herzenberg LA, Khosla C. *Proc Natl Acad Sci U S A.* 2000; 97:14766–14771. [PubMed: 11121076] (b) Salomon AR, Voehringer DW, Herzenberg LA, Khosla C. *Chem Biol.* 2001; 8:71–80. [PubMed: 11182320]
5. Gogvadze V, Orrenius S, Zhivotovsky B. *Trends in Cell Biology.* 2008; 18:165–173. [PubMed: 18296052]
6. (a) Salomon AR, Zhang YB, Seto H, Khosla C. *Org Lett.* 2001; 3:57–59. [PubMed: 11429871] (b) Wender PA, Jankowski OD, Tabet EA, Seto H. *Org Lett.* 2003; 5:2299–2302. [PubMed: 12816433] (c) Wender PA, Jankowski OD, Longcore K, Tabet EA, Seto H, Tomikawa T. *Org Lett.* 2006; 8:589–592. [PubMed: 16468718]
7. Degradation and semisynthesis: (a) Salomon AR, Zhang YB, Seto H, Khosla C. *Org Lett.* 2001; 3:57–59. [PubMed: 11429871] (b) Wender PA, Jankowski OD, Tabet EA, Seto H. *Org Lett.* 2003; 5:487–490. [PubMed: 12583750] (c) Wender PA, Jankowski OD, Tabet EA, Seto H. *Org Lett.* 2003; 5:2299–2302. [PubMed: 12816433] (d) Wender PA, Jankowski OD, Longcore K, Tabet EA, Seto H, Tomikawa T. *Org Lett.* 2006; 8:589–592. [PubMed: 16468718] (e) Lewis CA, Longcore KE, Miller SJ, Wender PA. *J Nat Prod.* 2009; 72:1864–1869. [PubMed: 19769383]
8. Total Synthesis: (a) Nicolaou KC, Li YW, Sugita K, Monenschein H, Guntupalli P, Mitchell HJ, Fylaktakidou KC, Vourloumis D, Giannakakou P, O'Brate A. *J Am Chem Soc.* 2003; 125:15443–15454. [PubMed: 14664590] (b) Schuppan J, Wehlan H, Keiper S, Koert U. *Chem Eur J.* 2006; 12:7364–7377. (c) Wehlan H, Dauber M, Fernaud MTM, Schuppan J, Keiper S, Mahrwald R,

- Garcia MEJ, Koert U. *Chem Eur J*. 2006; 12:7378–7397. (d) Ghidu VP, Wang JQ, Wu B, Liu QS, Jacobs A, Marnett LJ, Sulikowski GA. *J Org Chem*. 2008; 73:4949–4955. [PubMed: 18543990] (e) Ghidu VP, Ntai I, Wang JQ, Jacobs AT, Marnett LJ, Bachmann BO, Sulikowski GA. *Org Lett*. 2009; 11:3032–3034. [PubMed: 19552384]
9. (a) Wender PA, Gulledge AV, Jankowski OD, Seto H. *Org Lett*. 2002; 4:3819–3822. [PubMed: 12599467] (b) Pennington JD, Williams HJ, Salomon AR, Sulikowski GA. *Org Lett*. 2002; 4:3823–3825. [PubMed: 12599468]

apoptolidin A (R = Me; X = Y = OH, 1)
 apoptolidin B (R = Me; X = H; Y = OH, 2)
 apoptolidin C (R = Me; X = Y = H, 3)
 apoptolidin D (R = H; X = Y = OH, 4)

apoptolidin E (R = Sug, 5)
 apoptolidin F (R = H, 6)

Figure 1.
 Structures of apoptolidins A-F (1–6).

isoapoptolidin A (R = Me; X = Y = OH, 7)
 isoapoptolidin B (R = Me; X = H; Y = OH, 8)
 isoapoptolidin D (R = H; X = Y = OH, 9)

Figure 2.
 Structures of isoapoptolidins A, B and D (7–9).

Figure 3.
Selected ROESY (↵) and HMBC (↗) correlations establishing the structure of apoptolidin G (10).

Table 1
Comparison of ¹H NMR Data for Apoptolidin G and Apoptolidin A (ppm, CD₃OD, 600 MHz)

carbon	δ_H		carbon	δ_H		carbon	δ_H		carbon	δ_H	
	G	A		G	A		G	A		G	A
1			16	3.2	3.47	6-Me	1.59	1.97	1"	5.02	4.97
2			17	3.33	2.75	8-Me	1.08	1.17	2"	1.78, 1.97	1.84, 1.96
3	6.08	7.41	18	1.69, 2.41	1.78, 2.2	12-Me	1.73	1.71	3"		
4			19	5.2	5.32	22-Me	1.04	1.06	4"	3.3	3.37
5	5.87	6.23	20	3.79	3.57	24-Me	0.88	0.92	5"	3.72	3.7
6			21			17-OMe	3.56	3.4	6"	1.2	1.25
7	4.93	5.27	22	2.1	2.08	28-OMe	3.33	3.3	3"-Me	1.33	1.36
8	2.8	2.79	23	3.77	3.76	1'	4.79	4.85	1'''	4.82	4.86
9	3.77	3.87	24	1.7	1.76	2'	3.37	3.44	2'''	1.28, 2.43	1.32, 2.47
10	5.33	5.26	25	4.06	3.99	3'	3.7	3.76	3'''	3.17	3.21
11	6.21	6.21	26	1.44, 1.69	1.49, 1.62	4'	2.7	2.76	4'''	2.96	3.01
12			27	3.9	3.48	5'	3.72	3.78	5'''	3.17	3.24
13	5.68	5.71	28	3.38	3.36	6'	1.24	1.29	6'''	1.26	1.31
14	2.18, 2.41	2.09, 2.5	2-Me	2.01	2.14	4'-OMe	3.56	3.61	3'''-OMe	3.42	3.46
15	1.42, 1.73	1.44, 1.52	4-Me	1.7	2.21						

Table 2
Comparison of ^{13}C NMR Data for Apoptolidin G and Apoptolidin A (ppm, CD_3OD , 600 MHz)

carbon	δ_{C}		carbon	δ_{C}		carbon	δ_{C}		carbon	δ_{C}		carbon	δ_{C}	
	G	A		G	A		G	A		G	A		G	A
1	172.1	172.7	16	73.2	74.6	6-Me	16.1	16.6	1"	99.5	99.5	99.5	99.5	99.5
2	<u>128.7</u>	<u>123.7</u>	17	86.0	83.8	8-Me	18.4	18.4	2"	45.2	45.5	45.2	45.2	45.5
3	<u>138.4</u>	<u>149.2</u>	18	37.8	38.4	12-Me	12.0	12.2	3"	73.1	73.0	73.1	73.1	73.0
4	133.5*	133.1	19	75.8	72.4	22-Me	12.4	12.4	4"	86.0	85.8	86.0	86.0	85.8
5	<u>139.2</u>	<u>147.0</u>	20	76.2	75.4	24-Me	5.4	5.3	5"	67.5	67.4	67.5	67.5	67.4
6	132.9*	133.4	21	101.4	101.3	17-OMe	61.0	61.4	6"	18.0	19.0	18.0	18.0	19.0
7	<u>133.0</u>	<u>142.9</u>	22	36.8	36.4	28-OMe	59.5	59.5	3"-Me	22.7	22.9	22.7	22.7	22.9
8	39.6	38.9	23	77.3	73.8	1'	95.5	96.0	1'''	101.9	101.9	101.9	101.9	101.9
9	82.7	84.2	24	40.7	40.6	2'	73.9	73.6	2'''	37.3	37.2	37.3	37.3	37.2
10	126.4	126.4	25	68.6	69.4	3'	75.0	74.9	3'''	82.0	82.0	82.0	82.0	82.0
11	141.4	141.2	26	37.8	37.2	4'	87.6	87.4	4'''	77.0	77.1	77.0	77.0	77.1
12	135.1	134.8	27	75.8	76.8	5'	68.2	68.2	5'''	73.0	73.2	73.0	73.0	73.2
13	133.6	133.3	28	77.3	76.8	6'	18.4	18.4	6'''	18.3	18.4	18.3	18.3	18.4
14	24.1	24.7	2-Me	23.0	14.2	4'-OMe	61.0	61.1	3'''-OMe	57.3	57.4	57.3	57.3	57.4
15	36.8	36.4	4-Me	17.8	18.0									

* denotes interchangeable assignments